STOCK TITAN

Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Akero Therapeutics to present at H.C. Wainwright 7th Annual NASH Conference
Positive
  • Akero Therapeutics to present at H.C. Wainwright 7th Annual NASH Conference
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced management will present virtually at the H.C. Wainwright 7th Annual NASH Conference on Tuesday, October 24, 2023, at 12:00 p.m. E.T.

A live webcast of the fireside chat will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including NASH, a disease without any approved therapies. Akero's lead product candidate, EFX, is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and Twitter for more information.

Investor Contact:
Austin Murtagh
212.698.8696
IR@akerotx.com

Media Contact:
Sarah O’Connell
732.456.0092
soconnell@vergescientific.com


FAQ

When will Akero Therapeutics present at the H.C. Wainwright 7th Annual NASH Conference?

Akero Therapeutics will present at the H.C. Wainwright 7th Annual NASH Conference on Tuesday, October 24, 2023.

Where can I watch the live webcast of the fireside chat?

The live webcast of the fireside chat will be available through the investor relations section of Akero Therapeutics' website at www.akerotx.com.

Will there be an archived replay of the webcast?

Yes, an archived replay of the webcast will be available on Akero Therapeutics' website.

Akero Therapeutics, Inc.

NASDAQ:AKRO

AKRO Rankings

AKRO Latest News

AKRO Stock Data

1.36B
46.04M
5.77%
92.13%
11.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About AKRO

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.